Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence of BEVZ92 vs Avastin in mCRC
NCT02069704Phase 1Completed
- Sponsor
- mAbxience
- Start
- Oct 2014
- Primary completion
- Oct 2015
- Modality
- Monoclonal Antibodies
- Countries
- 5
01
Overview
Phase 1, randomised, open-label trial of BI 695502 in metastatic colorectal cancer (mCRC) (2 arms), sponsored by mAbxience. Primary endpoints: Area Under the Concentration-versus-time Curve and Area Under the Curve at Steady State. Started Oct 2014; status: completed.
02
Drugs
BI 695502
03
Conditions
metastatic colorectal cancer (mCRC)
Beyond the preview
Go deeper on NCT02069704.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02069704.